BBT-877 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	2

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05483907 (ClinicalTrials.gov)	February 21, 2023	27/7/2022	To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF	A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Idiopathic Pulmonary Fibrosis	Drug: BBT-877;Drug: Placebo	Bridge Biotherapeutics, Inc.	NULL	Recruiting	40 Years	N/A	All	120	Phase 2	United States;Australia;Israel
2	NCT03830125 (ClinicalTrials.gov)	February 13, 2019	31/1/2019	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects	A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects	Idiopathic Pulmonary Fibrosis	Drug: BBT-877, Single dose;Drug: Placebo group;Drug: BBT-877, Multiple doses	Bridge Biotherapeutics, Inc.	KCRN Research, LLC	Completed	19 Years	55 Years	All	88	Phase 1	United States